Add BrightSurf on Google Email

Science News for April 29, 2017


Serelaxin fails to meet primary endpoints in phase 3 RELAX-AHF-2 trial

Serelaxin, a hormone with vasodilatory effects, failed to improve cardiovascular outcomes in the phase 3 RELAX-AHF-2 trial. Despite initial promising results from previous studies, serelaxin showed no significant benefit in reducing worsening heart failure or all-cause mortality.

SourceEuropean Society of Cardiology·JournalThe Lancet·DateApr 29, 2017

Intervention reduced suicide attempts among at-risk emergency department patients

A multifaceted intervention lowered the relative risk of new suicide attempts by 20% in emergency department patients who received specialized screening, safety planning guidance, and periodic follow-up phone check-ins. Patients in the intervention group made 30% fewer total suicide attempts compared to those receiving standard ED care.

SourceBrown University·JournalJAMA Psychiatry·DateApr 29, 2017
SAMSUNG T9 Portable SSD 2TB

SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.